Research & Development

Schrödinger, Bayer collaborate to co-develop de novo design technology to accelerate drug discovery

Schrödinger and Bayer announced a five-year technology alliance to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative high-quality drugs.

Tyme, Eagle join forces to advance SM-88 in advanced cancers

Tyme Technologies and Eagle Pharmaceuticals have entered into a collaboration deal worth up to $40m restricted to the US for co-promoting the former’s lead compound SM-88 in advanced cancers.

SAB Biotherapeutics announces research collaboration with CSL Behring

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader CSL Behring.

Cancer Research UK, Bicycle Therapeutics collaborate on new immuno-oncology candidate development

Bicycle Therapeutics has joined hands with Cancer Research UK for the development of a new immune-oncology candidate.

GlycoMimetics, Apollomics announce collaboration and license agreement for GMI-1687

GlycoMimetics and Apollomics announced an exclusive collaboration and license agreement for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China.

Merck enters into $2.5bn oncology deal with Taiho and Astex

Merck has joined hands with Japan’s Taiho Pharmaceutical and the UK’s Astex Pharmaceuticals in an oncology collaboration worth $2.5bn.

Leap Therapeutics and BeiGene announce exclusive option and license agreement for DKN-01

Leap Therapeutics has announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in Asia (excluding Japan), Australia, and New Zealand.

Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics

Acceleron Pharma has entered into a pulmonary research and discovery collaboration agreement with Fulcrum Therapeutics.

Achillion shareholders approve agreement to be acquired by Alexion

Achillion Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals.